TARO-ROSUVASTATIN 40 MG
ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 40 MG · DIN 02382679 · SUN PHARMA CANADA INC
Health Canada status: MARKETED
What is TARO-ROSUVASTATIN?
TARO-ROSUVASTATIN 40 MG contains ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02382679, held by SUN PHARMA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Mar-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-ROSUVASTATIN used for?
Adjunct to diet for reduction of elevated Total-C, LDL-C, ApoB, TG and increasing HDL-C in hyperlipidemia/dyslipidemia. Prevention of major cardiovascular events (MI, stroke, revascularization).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02382679 |
|---|---|
| Brand name | TARO-ROSUVASTATIN |
| Generic / active ingredient | ROSUVASTATIN (ROSUVASTATIN CALCIUM) : 40 MG |
| Manufacturer | SUN PHARMA CANADA INC |
| Strength | 40 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA07 ROSUVASTATIN |
| AHFS class | 24:06.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Mar-2020 |
| Original market date | 2012-04-02 00:00:00 |
How is it administered?
Adults: 5-40 mg once daily. Usual start: 10 mg. Max 40 mg only for severe hypercholesterolemia. Pediatrics (10-17 yrs): 5-10 mg once daily. Take with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Protect from moisture.
How is it supplied?
High-density polyethylene (HDPE) bottles of 100 and 500 tablets.
Contraindications
Hypersensitivity; active liver disease; unexplained persistent transaminase elevations (>3x ULN); concomitant cyclosporine or sofosbuvir/velpatasvir/voxilaprevir; pregnancy; breast-feeding.
Warnings and precautions
Risk of myopathy/rhabdomyolysis (especially at 40 mg). Monitor liver function. Risk of increased blood glucose/HbA1c. 40 mg dose contraindicated in Asian patients and those with myopathy risk factors.
Is ROSUVASTATIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 30 Jul 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AA07 ROSUVASTATIN. 84 of 152 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-ROSUVASTATIN | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438925 |
| ACH-ROSUVASTATIN | 20 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438933 |
| ACH-ROSUVASTATIN | 40 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438941 |
| ACH-ROSUVASTATIN | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02438917 |
| AG-ROSUVASTATIN CALCIUM | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500140 |
| AG-ROSUVASTATIN CALCIUM | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500159 |
| AG-ROSUVASTATIN CALCIUM | 40 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500167 |
| AG-ROSUVASTATIN CALCIUM | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02500132 |
| APO-ROSUVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02337983 |
| APO-ROSUVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02337991 |
Who else supplies ROSUVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ROSUVASTATIN appears in 2950 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.